SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Human Genome Sciences, Inc. (HGSI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (58)2/26/1997 7:40:00 PM
From: Troll_29   of 1127
 
My point was that I do not believe the people on this thread who assert that the U of WA will eviscerate the value of HGSI by "making HGSI's database obsolete." Further the 3 million share offering may be construed in a positive light also. It is better for a company facing the expense of FDA required drug testing to have adequate resources available rather than to wait until their cash position erodes. A recent Business Week article discussed how Merck did a less costly test and now cannot obtain the full market for its drug. Any marketable product that HGSI develops should be fully tested to maximize the commercial value.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News